NCT01556646View on ClinicalTrials.gov

Effect of Tolvaptan on Cognitive Function in Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
CirrhosisHepatic EncephalopathyHyponatremia
Interventions
DRUG

Tolvaptan

15 to 30mg qd titrated to sodium concentration

Trial Locations (1)

23249

Hunter Holmes McGuire VA Medical Center, Richmond

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Hunter Holmes Mcguire Veteran Affairs Medical Center

FED

NCT01556646 - Effect of Tolvaptan on Cognitive Function in Cirrhosis | Biotech Hunter | Biotech Hunter